Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Receivables (2020 - 2025)

Historic Receivables for Gain Therapeutics (GANX) over the last 5 years, with Q3 2025 value amounting to $917094.0.

  • Gain Therapeutics' Receivables changed N/A to $917094.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $917094.0, marking a year-over-year change of. This contributed to the annual value of $494684.0 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Gain Therapeutics' Receivables stood at $917094.0.
  • Over the past 5 years, Gain Therapeutics' Receivables peaked at $1.5 million during Q2 2025, and registered a low of $4486.0 during Q1 2021.
  • Over the past 4 years, Gain Therapeutics' median Receivables value was $353166.0 (recorded in 2021), while the average stood at $475626.8.
  • As far as peak fluctuations go, Gain Therapeutics' Receivables skyrocketed by 181534.86% in 2021, and later crashed by 4659.92% in 2022.
  • Quarter analysis of 4 years shows Gain Therapeutics' Receivables stood at $163724.0 in 2021, then tumbled by 46.6% to $87430.0 in 2022, then surged by 465.81% to $494684.0 in 2024, then surged by 85.39% to $917094.0 in 2025.
  • Its Receivables stands at $917094.0 for Q3 2025, versus $1.5 million for Q2 2025 and $738961.0 for Q1 2025.